ArticleAnnals of translational medicine2020
Breakthrough 5-year survival with pembrolizumab in Keynote-001 study: horizon shifting in advanced non-small cell lung cancer with immune check point inhibition.
Article in Annals of translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 18 citations in OpenAlex.
- Checkpoint inhibitor-associated pneumonitis in non-small cell lung cancer: a cohort study with transcriptomic analysis of inflammatory mechanisms.BMC pulmonary medicine · 2025Article
- Assessing Second-Line Treatment Strategies and Outcomes in Epidermal Growth Factor Receptor (EGFR) Oncogene-Driven Stage IV Non-Small Cell Lung Cancer, Following a First-Line EGFR-TKI Therapy.Cancer reports (Hoboken, N.J.) · 2025Article
- Long-Term Outcomes and Toxicities in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Immunotherapy Containing Regimens.Cancer reports (Hoboken, N.J.) · 2025Article
- Combination of Vismodegib and Paclitaxel Enhances Cytotoxicity via Bak-mediated Mitochondrial Damage in EGFR-Mutant Non-Small Cell Lung Cancer Cells.Cell biochemistry and biophysics · 2024Article
- Investigation the effects of bee venom and H-dental-derived mesenchymal stem cells on non-small cell lung cancer cells (A549).Molecular biology reports · 2023Article
- [Role of Adverse Events Supervision in Clinical Trials in Neoadjuvant Treatment of Operable Stage III NSCLC].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2023Article
- [Research Progress of Anti-PD-1/PD-L1 Therapy for Non-small Cell Lung Cancer with EGFR Mutation].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2022Article
- Anti-Cancer Effects of Auranofin in Human Lung Cancer Cells by Increasing Intracellular ROS Levels and Depleting GSH Levels.Molecules (Basel, Switzerland) · 2022Article
- Quickly evolving near-infrared photoimmunotherapy provides multifaceted approach to modern cancer treatment.View (Beijing, China) · 2022Article
- CT-based radiomics in predicting pathological response in non-small cell lung cancer patients receiving neoadjuvant immunotherapy.Frontiers in oncology · 2022Article
- Identification of prognostically relevant gene signatures in lung squamous cell carcinoma by Lung Cancer Explorer.Translational cancer research · 2021Article
- [Application Progress of Immune Checkpoint Inhibitors in Oncogene-driven Advanced Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2021Review
Corrections and comments
- Commented on by
- Comment on
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.